Pharmacogenetic candidate genes for melanoma

Christopher Hull, April Larson, Sancy Leachman

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The incidence of melanoma is rising at an alarming rate and has become an important public health concern. If detected early, melanoma carries an excellent prognosis after appropriate surgical resection. Unfortunately, advanced melanoma has a poor prognosis and is notoriously resistant to radiation and chemotherapy. The relative resistance of melanoma to a wide-range of chemotherapeutic agents and high toxicity of current therapies has prompted a search for effective alternative treatments that would improve prognosis and limit side effects. Advances in molecular genetics are revealing in increasing detail the mechanisms responsible for the development of melanoma. Hopefully, elucidation of these pathways will provide a means of screening high-risk individuals and allow new drug development for prevention and treatment by identification of specific pharmacological targets. This review will summarize the genetics of melanoma with the goal of providing insights into potential pharmacogenetic candidate genes.

Original languageEnglish (US)
Pages (from-to)753-765
Number of pages13
JournalPharmacogenomics
Volume4
Issue number6
DOIs
StatePublished - Nov 2003
Externally publishedYes

Fingerprint

Pharmacogenetics
Melanoma
Genes
Molecular Biology
Therapeutics
Public Health
Pharmacology
Radiation
Drug Therapy
Incidence
Pharmaceutical Preparations

Keywords

  • Melanoma
  • Personalized medicine
  • Pharmacogenetics
  • Treatment

ASJC Scopus subject areas

  • Pharmacology
  • Genetics(clinical)

Cite this

Pharmacogenetic candidate genes for melanoma. / Hull, Christopher; Larson, April; Leachman, Sancy.

In: Pharmacogenomics, Vol. 4, No. 6, 11.2003, p. 753-765.

Research output: Contribution to journalArticle

Hull, Christopher ; Larson, April ; Leachman, Sancy. / Pharmacogenetic candidate genes for melanoma. In: Pharmacogenomics. 2003 ; Vol. 4, No. 6. pp. 753-765.
@article{17afc0e6a9184070bf0e79d4486c0202,
title = "Pharmacogenetic candidate genes for melanoma",
abstract = "The incidence of melanoma is rising at an alarming rate and has become an important public health concern. If detected early, melanoma carries an excellent prognosis after appropriate surgical resection. Unfortunately, advanced melanoma has a poor prognosis and is notoriously resistant to radiation and chemotherapy. The relative resistance of melanoma to a wide-range of chemotherapeutic agents and high toxicity of current therapies has prompted a search for effective alternative treatments that would improve prognosis and limit side effects. Advances in molecular genetics are revealing in increasing detail the mechanisms responsible for the development of melanoma. Hopefully, elucidation of these pathways will provide a means of screening high-risk individuals and allow new drug development for prevention and treatment by identification of specific pharmacological targets. This review will summarize the genetics of melanoma with the goal of providing insights into potential pharmacogenetic candidate genes.",
keywords = "Melanoma, Personalized medicine, Pharmacogenetics, Treatment",
author = "Christopher Hull and April Larson and Sancy Leachman",
year = "2003",
month = "11",
doi = "10.1517/phgs.4.6.753.22819",
language = "English (US)",
volume = "4",
pages = "753--765",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Pharmacogenetic candidate genes for melanoma

AU - Hull, Christopher

AU - Larson, April

AU - Leachman, Sancy

PY - 2003/11

Y1 - 2003/11

N2 - The incidence of melanoma is rising at an alarming rate and has become an important public health concern. If detected early, melanoma carries an excellent prognosis after appropriate surgical resection. Unfortunately, advanced melanoma has a poor prognosis and is notoriously resistant to radiation and chemotherapy. The relative resistance of melanoma to a wide-range of chemotherapeutic agents and high toxicity of current therapies has prompted a search for effective alternative treatments that would improve prognosis and limit side effects. Advances in molecular genetics are revealing in increasing detail the mechanisms responsible for the development of melanoma. Hopefully, elucidation of these pathways will provide a means of screening high-risk individuals and allow new drug development for prevention and treatment by identification of specific pharmacological targets. This review will summarize the genetics of melanoma with the goal of providing insights into potential pharmacogenetic candidate genes.

AB - The incidence of melanoma is rising at an alarming rate and has become an important public health concern. If detected early, melanoma carries an excellent prognosis after appropriate surgical resection. Unfortunately, advanced melanoma has a poor prognosis and is notoriously resistant to radiation and chemotherapy. The relative resistance of melanoma to a wide-range of chemotherapeutic agents and high toxicity of current therapies has prompted a search for effective alternative treatments that would improve prognosis and limit side effects. Advances in molecular genetics are revealing in increasing detail the mechanisms responsible for the development of melanoma. Hopefully, elucidation of these pathways will provide a means of screening high-risk individuals and allow new drug development for prevention and treatment by identification of specific pharmacological targets. This review will summarize the genetics of melanoma with the goal of providing insights into potential pharmacogenetic candidate genes.

KW - Melanoma

KW - Personalized medicine

KW - Pharmacogenetics

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0242391954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242391954&partnerID=8YFLogxK

U2 - 10.1517/phgs.4.6.753.22819

DO - 10.1517/phgs.4.6.753.22819

M3 - Article

C2 - 14596639

AN - SCOPUS:0242391954

VL - 4

SP - 753

EP - 765

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 6

ER -